Award
NIH Reporter #1R43CA310210-01A1
Enhancing NK Cell Engineering Through Optimized SoftPoration(TM) for Cell-Based Therapeutics
Recipient
OpenCell Technologies, Inc.
Award Amount
$287,125.00
Ceiling
$287,125.00
Awarded
September 15, 2026
Identifier
1R43CA310210-01A1
This award funds OpenCell Technologies to optimize their SoftPorationTM platform for engineering natural killer (NK) cells, aiming to improve cell-based cancer therapies by making the process faster, gentler, and more cost-effective.
Description
OpenCell Technologies is developing a simple, gentle method to perform NK cell engineering, preserving cell health and functionality and minimizing both monetary and time costs. The SoftPorationTM platform enables quick, gentle, and efficient engineering of NK cells for therapeutic use, aiming to increase patient access to these treatments.